Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects

2004 ◽  
Vol 25 (5-6) ◽  
pp. 495-520 ◽  
Author(s):  
J BONNEFONT
1990 ◽  
Vol 40 (7) ◽  
pp. 1441-1448 ◽  
Author(s):  
Khosrow Kashfi ◽  
Mervyn Israel ◽  
Trevor W. Sweatman ◽  
Ramakrishnan Seshadri ◽  
George A. Cook

1990 ◽  
Vol 267 (1) ◽  
pp. 273-276 ◽  
Author(s):  
M S R Murthy ◽  
R R Ramsay ◽  
S V Pande

The activities of carnitine palmitoyltransferases (CPTs) of mitochondrial outer and inner membranes and of peroxisomes have been studied with carnitine analogues, namely DL-thiolcarnitine, DL-sulphocarnitine and L-aminocarnitine, using palmitoyl-CoA or octanoyl-CoA as co-substrate. With sulphocarnitine, both of the mitochondrial CPTs and the malonyl-CoA-sensitive CPT of peroxisomes showed appreciable activity with palmitoyl-CoA, but relatively lower activity when octanoyl-CoA was the co-substrate. The soluble CPT of peroxisomes did not show any activity with sulphocarnitine in the presence of either acyl-CoA. With thiolcarnitine, all of the CPTs showed more activity with palmitoyl-CoA than with octanoyl-CoA. None of the CPTs showed any activity with aminocarnitine and palmitoyl-CoA, but when the acyl donor was octanoyl-CoA, both of the malonyl-CoA-sensitive CPT enzymes showed considerable activity, unlike the malonyl-CoA-insensitive CPT isoenzymes. Aminocarnitine inhibited palmitoylcarnitine formation by both of the mitochondrial CPTs and by the CPT of gradient-purified peroxisomes, but the purified peroxisomal soluble CPT was not inhibited. These results show that the interaction of CPT enzymes with carnitine analogues, as substrates or inhibitors, is influenced by the chain length of the acyl-CoA substrate, and that the use of the appropriate carnitine analogue and acyl-CoA is likely to be useful for the discrimination of the various CPT activities in CPT deficiency disorders.


1995 ◽  
Vol 306 (2) ◽  
pp. 379-384 ◽  
Author(s):  
G Asins ◽  
D Serra ◽  
G Arias ◽  
F G Hegardt

Carnitine palmitoyltransferase (CPT) I is expressed in the intestine of suckling rats; its mRNA increases very rapidly after birth, remains on a plateau until day 18 and decreases until weaning, when basal (adult) values are reached, which remain unchanged thereafter. CPT II mRNA values do not show any appreciable change in this period. CPT I and CPT II are expressed mainly in mucosa and, to a lesser extent, in the muscular part of the intestine. Intestinal expression of CPT I is maximal in duodenum and jejunum, whereas CPT II is expressed in a similar pattern throughout the whole intestine. Dam's milk may influence the intestinal expression of CPT I, since mRNA levels at birth are low but increase after the first lactation. Moreover, rats weaned at either day 18 or 21 decrease their mRNA levels. Apparently, CPT II gene expression is not influenced by the mother's milk. CPT I and CPT II are also expressed in the liver of suckling rats. Hepatic CPT I is maximal at day 3, and levels of CPT II mRNA do not change, in a similar fashion to that in intestine. The profile of expression of CPT I in liver and intestine strongly resembles that previously reported for mitochondrial 3-hydroxy-3-methyl-glutaryl-CoA synthase.


2005 ◽  
Vol 1 (5) ◽  
pp. 445-453 ◽  
Author(s):  
P. Savle ◽  
N. Neptune ◽  
Y. Yang ◽  
J. Rouden ◽  
B. Kite ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document